◌
Bioelectronics
Adaptive stimulation, multimodal sensing and bioelectronic interaction.
Aurealix
AdaptiveBioelectronic and BiopharmaceuticalTechnologies. AdaptiveBioelectronic andBiopharmaceuticalTechnologies.
Bioelectronics. Adaptive therapeutics. Probabilistic control.
Aurealix develops a technology-independent architecture for adaptive bioelectronic interaction, neurocartographic mapping, probabilistic physiological reasoning and biopharmaceutical therapeutic control.
◎
Neurocartography
Functional response mapping for personalized neuromodulation and stimulation planning.
↗
Biopharma
Probabilistic in vivo delivery, proteostasis concepts and hazard-function logic.
✓
Validation
First validation pathways focus on measurable, clinically relevant use cases.
Technology
One integrated architecture. Two development pillars.
Aurealix is structured around an integrated conceptual architecture with two complementary development pillars: bioelectronic MedTech and biopharmaceutical therapeutic control.
Pillar I
Bioelectronic MedTech.
Neurocartography, adaptive stimulation concepts and bioelectronic systems with spatiotemporal activation patterns, response-phase logic and physiological feedback.
Pillar II
Biopharmaceutical systems.
Probabilistic in vivo delivery for substances with physiological activity, using proteostasis modelling, tipping-point concepts, adaptive therapeutic logic and hazard functions.
Architecture — Version 2.0
Six scientific frameworks. One coherent system.
The Aurealix Architecture integrates AFN, APIM, NSPP, BNPSS, STM and APR across observation, adaptive reasoning, validation and longitudinal physiological reorganization.
Initial validation pathway
Acute and chronic pain relief.
Acute and chronic pain relief is positioned as the first clinical validation pathway for Aurealix's adaptive bioelectronic technologies.
The goal is to translate adaptive stimulation, neurocartographic response mapping and probabilistic control into measurable physiological outcomes, while preserving a broader roadmap for neuromodulation and adaptive therapeutics.
Intellectual property
Fifteen patent filings across adaptive technologies.
Aurealix is supported by a portfolio of fifteen patent filings spanning adaptive bioelectronic systems, neurocartographic knowledge models, probabilistic physiological control and adaptive therapeutic architectures.
Collaboration
Academic, clinical and industrial partners.
Aurealix welcomes discussions with universities, research institutes, clinical partners, technology companies and consortium initiatives interested in validation and translational development.
Identity